Plasma-Conditioned Liquids as Anticancer Therapies In Vivo: Current State and Future Directions

Plasma-conditioned liquids (PCL) are gaining increasing attention in the medical field, especially in oncology, and translation to the clinics is advancing on a good path. This emerging technology involving cold plasmas has great potential as a therapeutic approach in cancer diseases, as PCL have be...

Full description

Bibliographic Details
Main Authors: Xavi Solé-Martí, Albert Espona-Noguera, Maria-Pau Ginebra, Cristina Canal
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/13/3/452
_version_ 1797407536897327104
author Xavi Solé-Martí
Albert Espona-Noguera
Maria-Pau Ginebra
Cristina Canal
author_facet Xavi Solé-Martí
Albert Espona-Noguera
Maria-Pau Ginebra
Cristina Canal
author_sort Xavi Solé-Martí
collection DOAJ
description Plasma-conditioned liquids (PCL) are gaining increasing attention in the medical field, especially in oncology, and translation to the clinics is advancing on a good path. This emerging technology involving cold plasmas has great potential as a therapeutic approach in cancer diseases, as PCL have been shown to selectively kill cancer cells by triggering apoptotic mechanisms without damaging healthy cells. In this context, PCL can be injected near the tumor or intratumorally, thereby allowing the treatment of malignant tumors located in internal organs that are not accessible for direct cold atmospheric plasma (CAP) treatment. Therefore, PCL constitutes a very interesting and minimally invasive alternative to direct CAP treatment in cancer therapy, avoiding surgeries and allowing multiple local administrations. As the field advances, it is progressively moving to the evaluation of the therapeutic effects of PCL in in vivo scenarios. Exciting developments are pushing forward the clinical translation of this novel therapy. However, there is still room for research, as the quantification and identification of reactive oxygen and nitrogen species (RONS) in in vivo conditions is not yet clarified, dosage regimens are highly variable among studies, and other more relevant in vivo models could be used. In this context, this work aims to present a critical review of the state of the field of PCL as anticancer agents applied in in vivo studies.
first_indexed 2024-03-09T03:42:57Z
format Article
id doaj.art-eec8165aaff247e6a75109c59cbc38b3
institution Directory Open Access Journal
issn 2072-6694
language English
last_indexed 2024-03-09T03:42:57Z
publishDate 2021-01-01
publisher MDPI AG
record_format Article
series Cancers
spelling doaj.art-eec8165aaff247e6a75109c59cbc38b32023-12-03T14:38:13ZengMDPI AGCancers2072-66942021-01-0113345210.3390/cancers13030452Plasma-Conditioned Liquids as Anticancer Therapies In Vivo: Current State and Future DirectionsXavi Solé-Martí0Albert Espona-Noguera1Maria-Pau Ginebra2Cristina Canal3Biomaterials, Biomechanics and Tissue Engineering Group, Department Materials Science and Engineering, Escola d’Enginyeria Barcelona Est (EEBE), Universitat Politècnica de Catalunya (UPC), 08930 Barcelona, SpainBiomaterials, Biomechanics and Tissue Engineering Group, Department Materials Science and Engineering, Escola d’Enginyeria Barcelona Est (EEBE), Universitat Politècnica de Catalunya (UPC), 08930 Barcelona, SpainBiomaterials, Biomechanics and Tissue Engineering Group, Department Materials Science and Engineering, Escola d’Enginyeria Barcelona Est (EEBE), Universitat Politècnica de Catalunya (UPC), 08930 Barcelona, SpainBiomaterials, Biomechanics and Tissue Engineering Group, Department Materials Science and Engineering, Escola d’Enginyeria Barcelona Est (EEBE), Universitat Politècnica de Catalunya (UPC), 08930 Barcelona, SpainPlasma-conditioned liquids (PCL) are gaining increasing attention in the medical field, especially in oncology, and translation to the clinics is advancing on a good path. This emerging technology involving cold plasmas has great potential as a therapeutic approach in cancer diseases, as PCL have been shown to selectively kill cancer cells by triggering apoptotic mechanisms without damaging healthy cells. In this context, PCL can be injected near the tumor or intratumorally, thereby allowing the treatment of malignant tumors located in internal organs that are not accessible for direct cold atmospheric plasma (CAP) treatment. Therefore, PCL constitutes a very interesting and minimally invasive alternative to direct CAP treatment in cancer therapy, avoiding surgeries and allowing multiple local administrations. As the field advances, it is progressively moving to the evaluation of the therapeutic effects of PCL in in vivo scenarios. Exciting developments are pushing forward the clinical translation of this novel therapy. However, there is still room for research, as the quantification and identification of reactive oxygen and nitrogen species (RONS) in in vivo conditions is not yet clarified, dosage regimens are highly variable among studies, and other more relevant in vivo models could be used. In this context, this work aims to present a critical review of the state of the field of PCL as anticancer agents applied in in vivo studies.https://www.mdpi.com/2072-6694/13/3/452plasma-conditioned liquidscancerin vivocold atmospheric plasma
spellingShingle Xavi Solé-Martí
Albert Espona-Noguera
Maria-Pau Ginebra
Cristina Canal
Plasma-Conditioned Liquids as Anticancer Therapies In Vivo: Current State and Future Directions
Cancers
plasma-conditioned liquids
cancer
in vivo
cold atmospheric plasma
title Plasma-Conditioned Liquids as Anticancer Therapies In Vivo: Current State and Future Directions
title_full Plasma-Conditioned Liquids as Anticancer Therapies In Vivo: Current State and Future Directions
title_fullStr Plasma-Conditioned Liquids as Anticancer Therapies In Vivo: Current State and Future Directions
title_full_unstemmed Plasma-Conditioned Liquids as Anticancer Therapies In Vivo: Current State and Future Directions
title_short Plasma-Conditioned Liquids as Anticancer Therapies In Vivo: Current State and Future Directions
title_sort plasma conditioned liquids as anticancer therapies in vivo current state and future directions
topic plasma-conditioned liquids
cancer
in vivo
cold atmospheric plasma
url https://www.mdpi.com/2072-6694/13/3/452
work_keys_str_mv AT xavisolemarti plasmaconditionedliquidsasanticancertherapiesinvivocurrentstateandfuturedirections
AT albertesponanoguera plasmaconditionedliquidsasanticancertherapiesinvivocurrentstateandfuturedirections
AT mariapauginebra plasmaconditionedliquidsasanticancertherapiesinvivocurrentstateandfuturedirections
AT cristinacanal plasmaconditionedliquidsasanticancertherapiesinvivocurrentstateandfuturedirections